{
  "@context": {
    "dcterms": "http://purl.org/dc/terms/",
    "cito": "http://purl.org/spar/cito/",
    "deo": "http://purl.org/spar/deo/"
  },
  "@id": "https://hypothesis.bioagent.ai/mj3451c7obe",
  "@type": "deo:FutureWork",
  "cito:usesDataFrom": [
    "https://doi.org/10.1038/ncomms14207",
    "https://doi.org/10.1186/s13041-024-01028-8",
    "https://doi.org/10.1007/s11357-023-00927-x",
    "https://doi.org/10.1002/dad2.12391"
  ],
  "dcterms:references": [
    "# Noradrenergic Modulation of DOPAL Production as a Compensatory Mechanism in Early Alzheimer's Disease\\n\\n## 1. Background\\nIn Alzheimer's disease (AD) mouse models like Tg2576, dopaminergic neurons in the ventral tegmental area undergo selective degeneration during pre-plaque stages, while noradrenergic projections from the locus coeruleus remain preserved, as evidenced by unchanged noradrenaline outflow in the hippocampus. DOPAL (3,4-dihydroxyphenylacetaldehyde), a reactive dopamine metabolite produced by monoamine oxidase (MAO), has been shown to decrease Aβ oligomerization in human neuroblastoma cells, potentially offering protection against Aβ-mediated neurotoxicity. Dopaminergic system modulation through L-DOPA or monoamine oxidase inhibitors like selegiline has demonstrated therapeutic potential in AD models, suggesting complex interactions between catecholamine systems and amyloid pathology.\\n\\n## 2. Knowledge Gap\\nWhile both preserved noradrenergic function and DOPAL's anti-amyloidogenic effects have been separately observed, the potential functional relationship between intact noradrenergic transmission and regulation of DOPAL production as a compensatory mechanism in early AD remains unexplored. Specifically, it is unknown whether noradrenergic signaling actively modulates dopamine metabolism to maintain beneficial levels of DOPAL that could mitigate Aβ oligomerization.\\n\\n## 3. Central Hypothesis\\nPreserved noradrenergic projections in early Alzheimer's disease compensate for declining dopaminergic function by modulating DOPAL production through adrenergic receptor-mediated regulation of monoamine oxidase activity, thereby maintaining optimal levels of DOPAL that inhibit Aβ oligomerization.\\n\\n## 4. Proposed Mechanism\\n1. Noradrenaline released from preserved locus coeruleus projections activates β-adrenergic receptors in the hippocampus and other brain regions where dopaminergic function is compromised in early AD.\\n2. β-adrenergic receptor activation modulates MAO-B activity through cAMP-dependent signaling pathways, fine-tuning the rate of dopamine metabolism to DOPAL in regions receiving both noradrenergic and dopaminergic input.\\n3. This noradrenergic regulation maintains an optimal balance of DOPAL levels: sufficient to interact with Aβ monomers and inhibit oligomerization but not excessive enough to cause cytotoxicity through protein modification.\\n4. As dopaminergic neurons progressively degenerate, this noradrenergic compensatory mechanism becomes increasingly important for maintaining DOPAL's protective effects against Aβ aggregation.\\n5. The eventual decline of noradrenergic function in later disease stages removes this compensatory mechanism, accelerating Aβ oligomerization and plaque formation.\\n\\n## 5. Testable Predictions\\n1. Pharmacological blockade of β-adrenergic receptors in young Tg2576 mice should increase MAO-B activity, alter DOPAL levels, and accelerate Aβ oligomerization and plaque formation compared to untreated controls.\\n2. Selective lesioning of noradrenergic neurons (e.g., using DSP-4) in young AD model mice should lead to dysregulated dopamine metabolism, reduced DOPAL/dopamine ratios, and accelerated Aβ pathology compared to non-lesioned mice.\\n3. Treatment with norepinephrine reuptake inhibitors should enhance DOPAL-mediated inhibition of Aβ oligomerization in cellular and animal models of AD, an effect that would be blocked by MAO-B inhibitors.\\n\\n## 6. Potential Experimental Approaches\\n1. Use microdialysis combined with high-performance liquid chromatography to simultaneously measure noradrenaline, dopamine, DOPAL, and other catecholamine metabolites in the hippocampus of Tg2576 mice before and after pharmacological manipulation of noradrenergic transmission and MAO activity. Correlate these measurements with Aβ oligomer levels assessed by ELISA and immunohistochemistry.\\n2. Develop an ex vivo system using acute hippocampal slices from wild-type and AD model mice to examine how noradrenergic stimulation affects local DOPAL production and Aβ oligomerization in real-time, utilizing fluorescent Aβ species and DOPAL-sensitive probes with live imaging techniques.\\n\\nThis hypothesis integrates findings from multiple abstracts to propose a novel compensatory mechanism involving cross-talk between preserved noradrenergic function and dopamine metabolism in early Alzheimer's disease. It suggests that the maintenance of noradrenergic projections may serve a previously unrecognized protective function by optimizing DOPAL levels to counteract Aβ aggregation, potentially explaining why noradrenergic preservation might be important in early disease stages."
  ],
  "dcterms:subject": ["AD mouse models", "amyloid beta"],
  "dcterms:source": [
    "Noradrenaline outflow in the hippocampus did not differ between wild-type and Tg2576 mice at 6 months of age, suggesting preserved noradrenergic projections from the locus coeruleus.",
    "DOPAL, a dopamine metabolite, decreases Aβ oligomerization in human neuroblastoma cells, reducing the cytotoxic effects of Aβ."
  ],
  "dcterms:abstract": [
    "The study examines dopaminergic neuron loss in Alzheimers disease focusing on the ventral tegmental area VTA in Tg2576 mice The research demonstrates selective loss of dopaminergic neurons specifically in the VTA during pre plaque stages contrasting with Parkinsons disease where neurons are lost in the substantia nigra pars compacta but preserved in VTA Apoptotic cell death contributes to VTA dopaminergic neuron degeneration affecting dopamine release in the hippocampus and impacting synaptic plasticity particularly in the hippocampal CA1 region Reduced dopamine outflow in Tg2576 mice leads to memory deficits and impaired reward processing while noradrenaline outflow remains unchanged indicating preserved noradrenergic projections from the locus coeruleus The study investigated several treatments Levodopa L DOPA administration successfully rescued multiple deficits including CA1 synaptic plasticity dendritic spine density hippocampal post synaptic density composition memory function and food reward processing L DOPA was administered at 10 mg kg along with benserazide at 12 mg kg Similarly selegiline a monoamine oxidase B inhibitor improved dopamine outflow in the hippocampus restored synaptic plasticity dendritic spine density memory performance and reward processing The treatment also restored D1 receptors and GluA1 expression in hippocampal PSD fractions These findings establish a clear link between dopamine signaling memory formation and reward processing in Alzheimers disease with dopaminergic dysfunction occurring at early stages The research suggests potential therapeutic approaches through dopamine system modulation using established drugs like L DOPA and selegiline",
    "Dopamine plays important roles in cognitive function and inflammation and therefore is involved in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD). Drugs that increase or maintain dopamine levels in the brain could be a therapeutic strategy for AD. However, the effects of dopamine and its precursor levodopa (L‑DOPA) on Aβ/tau pathology in vivo and the underlying molecular mechanisms have not been studied in detail. Here, we investigated whether L‑DOPA treatment alters neuroinflammation, Aβ pathology, and tau phosphorylation in 5xFAD mice, a model of AD. We found that L‑DOPA administration significantly reduced microgliosis and astrogliosis in 5xFAD mice. In addition, L‑DOPA treatment significantly decreased Aβ plaque number by upregulating NEP and ADAM17 levels in 5xFAD mice. However, L‑DOPA‑treated 5xFAD mice did not exhibit changes in tau hyperphos‑phorylation or tau kinase levels. These data suggest that L‑DOPA alleviates neuroinflammatory responses and Aβ pathology but not tau pathology in this mouse model of AD.",
    "Alzheimer’s disease (AD) is an age-related disease, with loss of integrity of the blood–brain barrier (BBB) being an early feature. Cellular senescence is one of the reported nine hallmarks of aging. Here, we show for the first time the presence of senescent cells in the vasculature in AD patients and mouse models of AD.",
    "[18F]AZD4694 is an amyloid beta (Aβ) imaging agent used in several observational studies and clinical trials. This study assessed 146 individuals evaluated with [18F]AZD4694 at baseline and a 2‐year follow‐up, revealing longitudinal patterns of Aβ accumulation. Results showed that cognitively unimpaired older adults displayed subtle Aβ accumulation, while Aβ positive cases exhibited greater increases, underscoring the agent’s potential to monitor Aβ levels in clinical settings."
  ]
}
